At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 22 enrolled
Drug / intervention
emollient (Cetaphil cream)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Study Investigating the Effects of Early Skin Barrier Protection on the Development of Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating emollient (Cetaphil cream) for Atopic Dermatitis. Completed, enrolled 22 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether early use of a bland emollient in newborns, prior to the clinical signs of skin disease, will delay the onset or prevent the development of atopic dermatitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesUnited States
CollaboratorsGalderma R&D
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2006
Primary CompletionNov 2008
First PostedDec 2008
Study CompletionNov 2009
TodayJul 2026
First PostedDec 10, 2008
Enrollment StartNov 1, 2006
Primary CompletionNov 1, 2008
Study CompletionNov 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 17.6 years ago
Interventions
emollient (Cetaphil cream)drug
Cetaphil cream applied daily from birth